Knowledge Library

 Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. WuXi Advanced Technologies recently announced the expansion of its service capabilities by offering a fully integrated CAR-T cell therapy platform to help accelerate the timeline for cell and gene therapy development, manufacturing, and release while providing greater predictability. This …Read More >

The field of gene therapy has experienced significant growth in recent years. Adeno-associated virus (AAV)–mediated therapies account for ~70% of the gene therapy market. However, the manufacturing capacity for AAV vectors remains a critical bottleneck. WuXi Advanced Therapies launched a world-class AAV suspension platform early 2020. In this webinar, we will reveal the improvements that …Read More >

In recent years, the demand for cell and gene therapy has increased substantially. The success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality plasmid DNA, key prominent market challenges are capacity availability, accelerated turnaround time (TAT), and affordability. In this presentation, WuXi Advanced Therapies will …Read More >

The field of gene and cell therapies expand rapidly in the past several years. Lentiviral vectors have been in a great demand as gene carriers in this field, especially for ex vivo gene therapies. However, the large scale lentiviral vector production still remains significant challenges. WuXi Advanced Therapies have experience working with Lentivirus since 2015 …Read More >

AAV vectors are widely used in gene therapy, largely because they do not become integrated into the patient’s DNA and are safe from an immunogenicity perspective. AAVs also offer great versatility, with different targets possible using different serotypes. Relative to other vectors, AAVs are also generally produced at higher titers, which reduces costs. In addition, …Read More >